Healthpeak Properties (DOC) has drawn investor attention after its recent share performance, with the stock up about 7% over the past month and roughly 34% in the past 3 months.

At a share price of $22.08, Healthpeak Properties has recently seen momentum cool slightly, with the 7 day share price return down 1.12% after a strong 30 day gain of 7.39% and a 90 day share price return of 34.39%, while the 1 year total shareholder return of 25.19% contrasts with a 5 year total shareholder return that is down 21.14%, which may hint at improving sentiment following a weaker longer term experience.

If Healthpeak Properties has you thinking about where else capital might find fresh momentum, this could be a good time to broaden your search with 17 top founder-led companies

Bulls point to Healthpeak Properties’ recent rebound and apparent discount to intrinsic value, while bears highlight weaker long term returns and net income pressure, so do the current numbers lean more toward opportunity or caution?

Most Popular Narrative: 3% Overvalued

With Healthpeak Properties last closing at $22.08 against a narrative fair value of $21.44, the current price sits slightly ahead of that framework and puts the focus firmly on the assumptions behind it.

The analysts have a consensus price target of $21.44 for Healthpeak Properties based on their expectations of its future earnings growth, profit margins and other risk factors.

In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $3.2 billion, earnings will come to $167.7 million, and it would be trading on a PE ratio of 108.7x, assuming you use a discount rate of 8.1%.

Want to understand why this narrative still finds upside with falling earnings forecasts and modest revenue growth assumptions, all wrapped in an unusually high profit multiple? The key ingredients include slow profit compression, steady top line expectations, and a valuation level more commonly linked to higher growth profiles. Curious which precise earnings path and margin profile are used to defend that pricing? The full narrative lays out those moving parts in detail.

Result: Fair Value of $21.44 (OVERVALUED)

However, the Healthpeak Properties story could change quickly if credit stress among biotech tenants worsens or if higher capital costs make refinancing and redevelopment materially tougher.

Another View: Healthpeak Properties Through a Cash Flow Lens

While the analyst narrative pegs Healthpeak Properties at about 3% overvalued on its earnings based fair value of $21.44, our DCF model points in the opposite direction, with an estimated future cash flow value of $38.07. This suggests the stock trades at a steep discount. Which story do you think fits the business better?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Healthpeak Properties for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 38 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Balanced or conflicted by what you have seen so far on Healthpeak Properties? Take a closer look at the complete risk and reward profile and shape your own view with 1 key reward and 4 important warning signs

Looking for more investment ideas beyond Healthpeak Properties?

Before you move on from Healthpeak Properties, consider building a stronger watchlist by identifying a few high quality candidates from different corners of the market.

• Explore income opportunities by reviewing reliable payers and potential high yield candidates through the 7 dividend fortresses.
• Emphasize quality at a reasonable price by scanning companies that combine value characteristics with robust fundamentals using the 38 high quality undervalued stocks.
• Seek a steadier experience by concentrating on companies with more stable risk profiles via the 79 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.